It demonstrated the superiority of the anti PDL-1pembrolizumab, alone or in combination with chemotherapy (cisplatin or carboplatin and 5FU), over the standard platinum-5-fluorouracil-cetuximab regimen, in patients with HNSCC PDL-1 CPS positive (CPS > 1) [25]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.